BioCardia, Inc.
BCDA Healthcare Biotechnology
BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024. In the quarter to June 2026, EPS grew 67.5% and free cash flow fell 5.15%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow BCDA
BioCardia, Inc. (BCDA) P/E ratio
BioCardia, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 333× (June 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 34 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DARE Dare Bioscience, Inc. compare | n/m |
| TVRD Tvardi Therapeutics, Inc. compare | n/m |
| RVLP RVL Pharmaceuticals PLC compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| CNSY Cerenome, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| BCDA BioCardia, Inc. | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| CLVSQ Clovis Oncology, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)